Cassava Sciences, Inc. (NASDAQ:SAVA – Get Free Report) insider James William Kupiec sold 4,000 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $3.87, for a total value of $15,480.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Cassava Sciences Trading Down 2.6 %
NASDAQ:SAVA opened at $3.35 on Wednesday. The stock has a market capitalization of $161.17 million, a P/E ratio of -2.43 and a beta of -0.86. Cassava Sciences, Inc. has a 1 year low of $3.25 and a 1 year high of $42.20. The firm has a 50 day moving average of $23.95 and a 200-day moving average of $22.52.
Cassava Sciences (NASDAQ:SAVA – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.79. During the same quarter in the prior year, the business posted ($0.61) EPS. As a group, analysts forecast that Cassava Sciences, Inc. will post -3.97 EPS for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Report on SAVA
Institutional Trading of Cassava Sciences
Institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC acquired a new position in shares of Cassava Sciences in the 3rd quarter valued at approximately $10,610,000. KBC Group NV acquired a new position in shares of Cassava Sciences in the third quarter valued at approximately $57,000. CANADA LIFE ASSURANCE Co increased its position in shares of Cassava Sciences by 146.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company’s stock worth $191,000 after acquiring an additional 5,594 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Cassava Sciences by 1.4% during the first quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company’s stock worth $47,813,000 after acquiring an additional 31,854 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Cassava Sciences by 18.1% during the second quarter. Bank of New York Mellon Corp now owns 140,847 shares of the company’s stock worth $1,739,000 after acquiring an additional 21,558 shares during the period. Institutional investors and hedge funds own 38.05% of the company’s stock.
Cassava Sciences Company Profile
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
See Also
- Five stocks we like better than Cassava Sciences
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- What is the Euro STOXX 50 Index?
- Netflix Is On Track To Hit $1,000 By Christmas
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.